CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Barriers to immune cell infiltration in tumors.
Barriers to immune cell infiltration in tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤内免疫细胞浸润增加与患者生存改善相关,并可预测对免疫治疗的应答。因此,确定决定免疫浸润程度的因素至关重要,以便开发针对这些靶点进行干预的方法。T 细胞通过血管系统进入肿瘤组织,并受 T 细胞上的归巢受体与肿瘤血管内皮和肿瘤细胞巢表达的归巢受体配体(HRLs)之间相互作用的控制。HRLs 在肿瘤中常常缺失,也可能存在主动的浸润屏障。这些方面仍研究不足,但可能对增强免疫介导的肿瘤控制至关重要。多种瘤内和全身治疗策略显示出增强 T 细胞浸润的前景,包括已获批疗法和实验性疗法。本综述重点介绍免疫细胞浸润进入肿瘤的细胞内和细胞外决定因素、浸润屏障,以及为增强浸润和对免疫治疗应答而进行干预的方法。
Increased immune cell infiltration into tumors is associated with improved patient survival and predicts response to immune therapies.
Thus, identification of factors that determine the extent of immune infiltration is crucial, so that methods to intervene on these targets can be developed. T cells enter tumor tissues through the vasculature, and under control of interactions between homing receptors on the T cells and homing receptor ligands (HRLs) expressed by tumor vascular endothelium and tumor cell nests. HRLs are often deficient in tumors, and there also may be active barriers to infiltration.
These remain understudied but may be crucial for enhancing immune-mediated cancer control. Multiple intratumoral and systemic therapeutic approaches show promise to enhance T cell infiltration, including both approved therapies and experimental therapies. This review highlights the intracellular and extracellular determinants of immune cell infiltration into tumors, barriers to infiltration, and approaches for intervention to enhance infiltration and response to immune therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。